Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs01:28

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

329
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
329
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

201
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
201
Antidepressant Drugs: Overview01:25

Antidepressant Drugs: Overview

377
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
377
Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

354
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
354
Diagnostic and Statistical Manual of Mental Disorders (DSM)01:27

Diagnostic and Statistical Manual of Mental Disorders (DSM)

48
The Diagnostic and Statistical Manual of Mental Disorders (DSM) serves as the primary classification system for mental health disorders, providing standardized diagnostic criteria for clinicians and researchers. First published by the American Psychiatric Association (APA) in 1952, the DSM has undergone several revisions to reflect evolving psychiatric understanding. The fifth edition, DSM-5, released in 2013, introduced key updates that expanded diagnostic categories and modified diagnostic...
48
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

103
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
103

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Proxy reports on the EQ-5D-5L in residential aged care facilities: a validation study.

Health and quality of life outcomes·2026
Same author

Serotonin reuptake inhibiting antidepressants: A trigger for visual snow syndrome?

The International journal of risk & safety in medicine·2025
Same author

Interaction Between Chronotype and the Timing of Antihypertensive Medication on Cardiovascular Events and Death.

Journal of the American Heart Association·2025
Same author

Primary care insights on the management of diabetes: results from a mixed method study of care changes and impacts during the COVID-19 pandemic.

Family practice·2025
Same author

The implementation and evaluation of the Ontario COVID@Home Clinical Primary Care Pathway.

Family practice·2025
Same author

Describing primary care patterns before and during the COVID-19 pandemic across Canada: a quasi-experimental pre-post design cohort study using national practice-based research network data.

BMJ open·2024

Related Experiment Video

Updated: Jun 12, 2025

Methods to Quantify Pharmacologically Induced Alterations in Motor Function in Human Incomplete SCI
14:55

Methods to Quantify Pharmacologically Induced Alterations in Motor Function in Human Incomplete SCI

Published on: April 18, 2011

13.7K

Post-SSRI sexual dysfunction: barriers to quantifying incidence and prevalence.

David Healy1, Dee Mangin2,3

  • 1Data Based Medicine, Wales, UK.

Epidemiology and Psychiatric Sciences
|September 18, 2024
PubMed
Summary
This summary is machine-generated.

Post-SSRI sexual dysfunction (PSSD) can persist after stopping selective serotonin reuptake inhibitors (SSRIs). This commentary discusses PSSD incidence, prevalence, and challenges in its quantification and diagnosis.

Keywords:
adverse effectsantidepressantssexual dysfunctionsuicide

More Related Videos

Signal Attenuation as a Rat Model of Obsessive Compulsive Disorder
09:29

Signal Attenuation as a Rat Model of Obsessive Compulsive Disorder

Published on: January 9, 2015

15.4K
The Forced Swim Test as a Model of Depressive-like Behavior
05:42

The Forced Swim Test as a Model of Depressive-like Behavior

Published on: March 2, 2015

37.2K

Related Experiment Videos

Last Updated: Jun 12, 2025

Methods to Quantify Pharmacologically Induced Alterations in Motor Function in Human Incomplete SCI
14:55

Methods to Quantify Pharmacologically Induced Alterations in Motor Function in Human Incomplete SCI

Published on: April 18, 2011

13.7K
Signal Attenuation as a Rat Model of Obsessive Compulsive Disorder
09:29

Signal Attenuation as a Rat Model of Obsessive Compulsive Disorder

Published on: January 9, 2015

15.4K
The Forced Swim Test as a Model of Depressive-like Behavior
05:42

The Forced Swim Test as a Model of Depressive-like Behavior

Published on: March 2, 2015

37.2K

Area of Science:

  • Neuroscience
  • Pharmacology
  • Psychiatry

Background:

  • Selective serotonin reuptake inhibitors (SSRIs) are widely prescribed antidepressants.
  • Sexual dysfunction is a known SSRI side effect, but persistent dysfunction after cessation is recognized as Post-SSRI Sexual Dysfunction (PSSD).
  • PSSD symptoms include genital numbness, anorgasmia, decreased libido, and erectile dysfunction.

Purpose of the Study:

  • To provide a commentary on the incidence and prevalence of PSSD.
  • To outline obstacles in quantifying PSSD occurrence.
  • To discuss challenges in PSSD diagnosis and public awareness.

Main Methods:

  • Review of academic literature.
  • Synthesis of clinical and research experience.
  • Analysis of factors hindering PSSD quantification and diagnosis.

Main Results:

  • Quantifying PSSD incidence and prevalence is challenging due to methodological difficulties.
  • Patient-related factors (embarrassment, unawareness) and healthcare system factors impede accurate assessment.
  • A formal definition and diagnostic criteria for PSSD have been established, alongside a MedDRA code.

Conclusions:

  • PSSD is a complex condition with significant challenges in determining its true prevalence.
  • Addressing patient and healthcare provider awareness is crucial for improved diagnosis and management.
  • Further research and regulatory adoption of diagnostic tools are needed for PSSD recognition.